Loading...
KOD
XNAS
Market cap6.35bUSD
Nov 20, Last price  
97.17USD
1D
-0.75%
1Q
153.51%
IPO
831.64%
Name

Kodiak Sciences Inc

Chart & performance

D1W1MN
XNAS:KOD chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
136.70%
Shs. 5Y
3.07%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-230m
L+30.51%
-17,132,000-27,936,000-41,443,000-47,365,000-133,096,000-266,990,000-333,823,000-260,491,000-176,207,000-229,967,000
CFO
-136m
L+15.93%
-16,047,000-17,655,000-29,031,000-39,146,000-83,428,000-182,270,000-206,459,000-154,183,000-117,319,000-136,008,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Key people

Victor Perlroth
Chairman of the Board, Chief Executive Officer, Co-Founder · since 2009
John Borgeson
Chief Financial Officer, Executive Vice President, Secretary · since 2022
Independent Director · since 2015
Independent Director · since 2020
Independent Director · since 2018
Independent Director · since 2018
Lead Independent Director · since 2018
Taiyin Yang
Independent Director · since 2019
IPO date
Oct 04, 2018
Employees
118
Domiciled in
US
Incorporated in
US
Legal address
C/O Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
US
Headquarters
1200 Page Mill Road
Palo Alto, CA 94304
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT